Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial

Twenty-two patients with refractory malignancies were treated with four escalating weekly doses of recombinant interleukin 2 (IL2), given either i.v. by 2- or 24-h infusion, or s.c. A 1-wk washout period between each dose of IL2 was provided for the evaluation for pharmacokinetic and immunomodulator...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1987-08, Vol.47 (15), p.4202-4207
Hauptverfasser:	THOMPSON, J. A, LEE, D. J, WELBY COX, W, LINDGREN, C. G, COLLINS, C, NERAAS, K. A, DENNIN, R. A, FEFER, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies - immunology Antineoplastic agents Biological and medical sciences Biological Availability Chemotherapy Drug Evaluation Fever - chemically induced Hypotension - chemically induced Immunity, Cellular - drug effects Infusions, Intravenous Injections, Subcutaneous Interleukin-2 - adverse effects Interleukin-2 - metabolism Interleukin-2 - pharmacology Lymphocyte Activation - drug effects Lymphopenia - chemically induced Medical sciences Neoplasms - drug therapy Neoplasms - metabolism Pharmacology. Drug treatments Recombinant Proteins - adverse effects Recombinant Proteins - immunology Recombinant Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!